Empowering Global Biopharma with cGMP Peptide Active Pharmaceutical Ingredients, High-Purity Synthesis Platforms, and End-to-End Regulatory DMF Support.
Explore our primary portfolio of commercially available peptide active pharmaceutical ingredients produced under strict cGMP compliance for global distribution.
Understanding macro procurement trends, technological evolution, and industrial scale-up dynamics in peptide active pharmaceutical ingredients.
The global pharmaceutical ecosystem is experiencing a profound paradigm shift towards peptide-based therapeutics. Operating at the intersection of biological macromolecules and small-molecule synthetic pharmaceuticals, Peptide Active Pharmaceutical Ingredients (APIs) offer unprecedented target selectivity, high biological efficacy, and favorable safety profiles. Driven by breakthrough innovations in metabolic medicine—most notably GLP-1 and dual GLP-1/GIP receptor agonists such as Semaglutide, Liraglutide, and Tirzepatide—the demand for scalable, cGMP-compliant peptide synthesis has escalated dramatically on a global scale.
As contract development and manufacturing organizations (CDMOs) and primary peptide API producers adapt to this surging volume, technical challenges surrounding Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), and hybrid synthesis methodologies have taken center stage. Managing epimerization, suppressing unwanted aggregation during cleavage, optimizing preparative HPLC purification columns, and maximizing overall atom economy represent critical core competencies that separate generic chemical suppliers from elite peptide manufacturing partners.
Engineered for quality, flexibility, and worldwide regulatory compliance.
About Gentolex: Creating strategic opportunities connecting the global pharmaceutical market with guaranteed products and certified cGMP infrastructure.
Gentolex’s overarching goal is to create seamless opportunities connecting the global pharmaceutical industry with better services, absolute batch-to-batch consistency, and guaranteed product quality. Up to date, Gentolex Group has been serving valued customers across more than 10 countries worldwide. To provide tailored localized support, dedicated regional operations and representative centers have been established in key hubs, including Mexico and South Africa.
Our expansive factory footprint spans over 250,000 square meters constructed under strict international standard guidelines. This vast infrastructure offers maximum flexibility, scalable tonnage capacities, and cost-effective batch output for large-scale industrial chemical synthesis.
Gentolex offers an extensive range of APIs and advanced intermediates for development study, pilot trials, and commercial application with cGMP standard support from long-term collaborative partnerships. Full DMF documents and Certificates of Analysis (COA) are fully supported.
Our core services encompass supplying therapeutic peptide APIs and Custom Peptides, FDF (Finished Dosage Form) licensing out, technical consultation, automated peptide product line setup, analytical laboratory construction, and streamlined supply chain management.
For biopharma clients who prefer to avoid the complexity of managing multiple vendors, we provide custom centralized procurement services utilizing our comprehensive, audit-verified chemical and pharmaceutical supply chain ecosystem.
Overcoming manufacturing bottlenecks through state-of-the-art solid-phase, liquid-phase, and bio-enzymatic coupling technologies.
Our production facilities utilize modern high-throughput microwave-assisted and continuous-flow automated SPPS reactors. By closely monitoring resin swelling properties, utilizing optimized Fmoc/tBu protection strategies, and deploying coupling reagents such as DIC/Oxyma and HATU, we minimize racemization during difficult sequence assemblies. This results in crude peptides with remarkably low byproduct rates, simplifying downstream purification.
For long-chain peptides exceeding 30–40 amino acids (such as Semaglutide, Tirzepatide, and Leuprorelin), pure solid-phase methods often suffer from exponential yields reduction. Gentolex employs advanced hybrid strategies: short protected peptide fragments are synthesized via high-yield SPPS, purified, and subsequently condensed in liquid phase (LPPS). This approach optimizes raw material utilization, drastically lowers trifluoroacetic acid (TFA) consumption, and delivers superior operational scalability.
Environmental stewardship and regulatory standards mandate the reduction of toxic solvents like DMF and DCM. Gentolex integrates green solvent alternatives (including 2-MeTHF and CPME) alongside industrial-scale reverse-phase preparative HPLC (RP-HPLC) purification systems. Dynamic axial compression (DAC) columns operating with high-efficiency C18/C8 stationary phases enable separation of closely related diastereomers, achieving final API purities exceeding 99.0% with tightly controlled residual TFA, counterion, and heavy metal concentrations.
Peptide stability relies heavily on solid-state freeze-drying control. Our cGMP lyophilization suites maintain precise freezing profiles, primary drying vacuum control, and secondary drying temperature ramps. This guarantees optimal moisture content (<1.0%), controlled polymorph formation, excellent cake integrity, and long-term shelf stability under standard and accelerated storage conditions.
Discover our extended line of high-purity peptides covering metabolic regulation, reproductive health, gastrointestinal care, and neurological study.
In-depth technical breakthroughs and product developments in novel peptide raw materials.
Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous tuftsin fragment engineered for enhanced stability and neuroactive potency...
View Details
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies and pharmaceutical research organizations worldwide, adhering strictly to global quality control standards...
View Details
BPC-157 API is a synthetic pentadecapeptide gaining substantial scientific interest due to its biological activities related to tissue repair, gastrointestinal mucosal protection, angiogenesis, and inflammatory pathway regulation. Explore our batch testing data...
View Details
With ongoing developments in neuroscience and peptide technology, neuroactive peptides have become a focal point of scientific investigation. Semax, a synthetic fragment derived from ACTH, exhibits unique molecular characteristics under standardized synthesis...
View Details
SS-31 API (Elamipretide, MTP-131, Bendavia) is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, supporting cellular bioenergetics and preserving structural integrity...
View DetailsPartnering with leading pharmaceutical manufacturers, biotech institutions, and research entities across 10+ countries.
Detailed answers regarding regulatory DMF filings, batch consistency, quality analytical testing, and global delivery SLA.
